Kinder Morgan, Roche Go Shopping — Monday’s IP Market Recap

by Kyle Woodley | October 17, 2011 4:42 pm

Investors got an M&A treat Monday that offered two different views of the financial food chain — in the pharmaceutical sector, a big fish ate a little fish, and in the energy sector, a big fish ate … well, another pretty big fish.

The big news of the day was the pairing of North America’s largest natural gas pipeline operators through Kinder Morgan Energy Partners LP’s (NYSE:KMP[1]) $21 billion acquisition — announced Sunday — of El Paso Corp. (NYSE:EP[2]). While natural gas prices have been in retreat[3] — from $4.40 per million Btu (MMBtu) at the end of July to just $3.54 per MMBtu last week — more energy companies are hitting the shale fields to capture what’s expected to be a growing source of energy throughout the continent for the next few years.

According to Reuters, Kinder Morgan will buy El Paso at a 37% premium[4] to its Oct. 14 value. On the first trading day following the deal, EP stock took a roughly 25% booster shot, from 19.59 at Friday’s close to $24.45 at Monday’s end. However, El Paso Pipeline Partners, L.P. (NYSE:EPB[5]) fell 10.05% to $3.82. Everything Kinder shined, with KMP stock ending the day up 5.08% at $75.14, Kinder Morgan Management (NYSE:KMR[6]) up 5.28% to $65.76 and Kinder Morgan Inc. (NYSE:KMI[7]) up 4.83% to $28.19.

More quietly heralded on Monday was European pharmaceutical giant Roche Holding AG’s $230 million purchase[8] of American small-cap Anadys Pharmaceuticals (NASDAQ:ANDS[9]). The acquisition was made to bolster the Swiss company’s presence in the Hepatitis C medicine market, as well as to help it move into treatment of more widespread diseases.

While Roche already produces Pegasys, which totaled $1.5 billion in sales in 2010, Anadys’ experimental drug Setrobuvir has shown promise and could be another way to treat the 180 million-plus people globally suffering from hepatitis. Roche, which trades primarily on the SIX Swiss Exchange, was down 0.77% Monday. The real winners were Anadys shareholders, who saw this particular investment gain 253% (to $3.67), just by waking up in the morning.

In the run-up to Apple’s (NASDAQ:AAPL[10]) earnings report, due out Tuesday after the bell, AAPL shares slid about half a percent to $419.99. This movement came despite a report out Monday that Apple had sold 4 million iPhone 4S units in just three days[11], crushing even the paces of previous blockbuster sales for the iPhone 3G, iPhone 3GS and iPhone 4.

Three Up

• Walgreen (NYSE:WAG[12]) was up 2.7% (89 cents) to $33.89.
• China Unicom (NYSE:CHU[13]) was up 2.04% (39 cents) to $19.51.
• Family Dollar (NYSE:FDO[14]) was up 1.69% (92 cents) to $55.32.

Three Down

• Green Mountain Coffee Roasters (NASDAQ:GMCR[15]) was down 10.41% ($9.59) to $82.50.
• Alcoa (NYSE:AA[16]) was down 6.63% (68 cents) to $9.58.
• Research In Motion (NASDAQ:RIMM[17]) was down 6.55% ($1.57) to $22.40.

One Down Late

• Crocs, Inc. (NASDAQ:CROX[18]) was down 35.06% ($9.34) to $17.30 in after-hours trading.

As of this writing, Kyle Woodley did not own a position in any of the aforementioned stocks. Check out recaps from previous trading days here[19].

Source URL: https://investorplace.com/2011/10/kinder-morgan-el-paso-roche-anadys-pharmaceutical-market-recap/

---